Logotype for Compass Therapeutics Inc

Compass Therapeutics (CMPX) investor relations material

Compass Therapeutics Guggenheim Securities 2nd Annual Healthcare Innovation Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Compass Therapeutics Inc
Guggenheim Securities 2nd Annual Healthcare Innovation Conference summary10 Nov, 2025

Pipeline overview and clinical progress

  • Four antibody-based oncology drugs in the clinic by early next year, including bispecific and next-gen candidates.

  • Lead program is a DLL4 VEGFA bispecific antibody in a randomized trial for advanced biliary tract cancer.

  • Recent phase one data announced for a novel PD-1, PD-L1 bispecific with responses in post-checkpoint inhibitor patients.

  • IND filing for a PD-1 VEGFA bispecific antibody on track for this quarter, with preclinical data presented at SITSI.

  • Multiple clinical trial readouts expected in 2026, with funding secured into 2028.

COMPANION-002 study and commercial opportunity

  • Second-line BTC market in the US estimated at 15,000 patients annually, representing a commercial opportunity exceeding $1 billion.

  • COMPANION-002 trial showed statistically significant improvement in response rate by adding Tuvesimig to paclitaxel (p=0.031).

  • Marked reduction in progressive disease at week eight in the combination arm (16.2% vs. 42.1% control).

  • No new safety signals identified; study overseen by a data safety monitoring committee.

  • Progression-free survival (PFS) and overall survival (OS) data expected in late Q1 next year.

Regulatory and clinical strategy

  • Hierarchical testing used for endpoints; positive response rate allows full alpha to roll over to PFS and OS.

  • Fewer deaths than projected suggest a possible survival benefit.

  • FDA required paclitaxel as the control arm; FOLFOX not mandated despite NCCN guidelines.

  • Market research indicates even modest clinical benefits would be meaningful to clinicians.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Compass Therapeutics earnings date

Logotype for Compass Therapeutics Inc
Stifel 2025 Healthcare Conference12 Nov, 2025
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Compass Therapeutics earnings date

Logotype for Compass Therapeutics Inc
Stifel 2025 Healthcare Conference12 Nov, 2025

The essential earnings season companion

The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics primarily targeting oncology. The company’s research centers on the interaction between angiogenesis, the immune system, and tumor growth. Its pipeline includes novel therapeutic candidates designed to modulate key biological pathways to elicit an effective anti-tumor response. This includes strategies to influence the tumor microvasculature, activate immune cells, and overcome immunosuppressive mechanisms employed by tumors. The company is headquartered in Boston, Massachusetts, and its shares are listed on the NASDAQ.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage